GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
J

Jetema Co 216080.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

5,700

-2.23%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Jetema Co

Its shares trade on KOSDAQ under the ticker 216080.KQ. It has been listed since 14 November 2019. In the fiscal year to 31 December 2025, it reported revenue of ₩76.90bn and a net loss of ₩6.60bn. At that date it held total assets of ₩209.14bn and shareholders' equity of ₩65.46bn.

Jetema Co., Ltd. is engaged in the manufacturing and distributing of aesthetic products, including dermal filler, a thread, a botulinum toxin and other medical devices. The company is headquartered in Wonju, Gangwon-Do. The company went IPO on 2019-11-14. CO,.LTD is a Korea-based company principally engaged in the development and manufacturing of hyaluronic acid fillers used for facial beauty and other medical devices. The firm manufactures and sells medical devices for improvement of wrinkle, contour and volume. In addition, the Company also engages in the manufacturing and sale of laser equipment used for treatment of leukoplakia, psoriasis and alopecia areata, lifting medical device epiticons, cosmetic mask packs, pharmaceutical excaine creams as well as others.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
14 Nov 2019
Employees
187
Website
jetema.com ↗

Leadership

Pay as last reported

  • Jae Yeong KimCo-Chief Executive Officer, Director, since 2023
  • Jeong Seon NamCo-Chief Executive Officer, Director, since 2023
  • Hyeong Seok KimChief Financial Officer, Assistant Managing Director
  • Seung Bo MoonInternal Auditor
  • On LeeNon-Executive Independent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Manufactures and distributes aesthetic products including dermal fillers and botulinum toxin.
  • Headquartered in Wonju, Gangwon-Do with 187 employees.
  • Offers a range of medical devices for facial beauty and medical treatments.

Weaknesses

  • Limited to aesthetic and medical device manufacturing without broader product diversification.
  • Relies on a single sector (Health Care) for operations.
  • No mention of international market presence or expansion strategies.

Opportunities

  • Potential growth in the aesthetic and medical device market in South Korea.
  • Expansion into new medical device applications beyond current offerings.
  • Increased demand for non-invasive cosmetic procedures globally.

Threats

  • Competition from established pharmaceutical companies in the aesthetic sector.
  • Regulatory challenges in the medical device industry.
  • Dependence on a single market (South Korea) for revenue.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.